Biotech company Neurotech Pharmaceuticals this month received regulatory approval for its treatment of a a neurodegenerative ...

(TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI ...

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

Symptom severity, meibum quality, and telangiectasia are factors affecting prognostic outcomes for intense pulsed light therapy.

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

The US Food and Drug Administration (FDA) has approved the biologics license application (BLA) for Encelto (revakinagene ...

The U.S. Food and Drug Administration (FDA) has announced significant advancements in medical treatments, including the ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...

MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.